Niche market focus Cyclopharm operates in nuclear medicine with Technegas for lung ventilation imaging, presenting an opportunity to upsell complementary imaging solutions, consumables, and services to a specialized hospital and imaging center network.

ASX listed credibility As an ASX-listed medical device company with a defined product for pulmonary imaging, there is potential to engage procurement teams at mid to large hospitals seeking proven, compliant imaging agents and associated PAS consumables.

Product expansion With Ultralute planned release to improve radiopharmaceutical production efficiency, there is a cross-sell potential to radiopharmacies and nuclear medicine departments looking to optimize manufacturing workflows and reduce costs.

Growth potential Despite current revenue in the low range, the combination of a flagship imaging agent and a forthcoming production enhancement positions Cyclopharm for channel partnerships with larger imaging equipment and service providers seeking integrated solutions.

Competitive positioning Technegas is a well-known lung ventilation agent with expanding indications; engage with hospital buyers and distributors competing in nuclear medicine to differentiate through efficiency, reliability, and favorable total cost of ownership for consumables and support.